Quantitative analysis of vitreous changes in intraocular inflammation following faricimab treatment in a real world setting.

BACKGROUND

To analyze the incidence, and clinical characteristics of intraocular inflammation (IOI) associated with faricimab in a tertiary center in Austria.

METHODS

A retrospective analysis of IOI cases following intravitreal faricimab injections in the Kepler University Hospital Linz, Austria. Clinical data was analyzed from January 2023, until March 10th 2025. Clinical and optical coherence tomography (OCT) findings including vitreous changes via mean vitreous grey value (MVGV) were evaluated.

RESULTS

A total of 7333 intravitreal injections of faricimab for a total of 1137 patients were applied during the observation period. We identified 11 eyes with an IOI after faricimab injection with a mean follow up of 22.5 days (range 3–42 days) which corresponds to an incidence of IOI of 0.15% per injection. Quantitative OCT analysis showed a significant rise in mean vitreous gray value during IOI (p = 0.002), which returned to baseline after treatment (p = 0.63). A significant, fully reversible increase in vitreous haze during IOI episodes was shown. Clinical findings included both anterior and posterior segment inflammation in the absence of pain or occlusive vasculitis.

CONCLUSION

The results suggest a low incidence of IOI after faricimab injections, comparable to registration trials. MVGV analysis via OCT proved to be sensitive and reproducible. All cases resolved with topical treatment. Intravitreal therapy with faricimab has shown to have a low risk of adverse events.